Umabs DB is currently the most comprehensive global database for antibody drugs, recording nearly 10,000 antibody drugs from clinical trials to commercialization, covering over 1,600 targets and more than 2,400 disease types, with 2,900+ research institutions involved, encompassing various professional information such as drug protein sequences, patents, and clinical data. The Umabs DB drug database has officially launched and can be accessed at www.umabs.com for a 7-day free trial.
East China Pharmaceutical has long been invested in the ADC field, starting from the introduction of ImmunoGen’s FRα ADC drug mirvetuximab soravtansine for the Greater China region in 2020, to acquiring shares in the emerging ADC company Heidelberg Pharma in 2022 and introducing four ADC pipelines, and recently establishing its own ADC platform ecosystem.
This year, East China Pharmaceutical has continuously filed for four self-developed platform ADC drugs, three of which have rapidly initiated clinical trials, covering multiple innovative targets, with a strong focus on gastrointestinal tumors, demonstrating a vigorous momentum.
Three ADC drugs related to topoisomerase inhibitors were showcased at this year’s AACR conference, where the product structure was still represented in schematic form, and the structure of the CPD3 toxin was not disclosed. Recently, the PCT patent update revealed East China Pharmaceutical’s first public disclosure of its self-developed ADC platform (WO2025180469).
The disclosed patent for the MUC17 ADC drug HDM2012 shows that CPD3 has undergone optimization for anti-reverse reactions at the junction, connecting the VA backbone for PEGylation, with the toxin being Exatecan and a DAR value of 8.
Compared to Deruxtecan, the ADC drugs carrying CPD3 demonstrated complete tumor suppression, showing significant activity advantages.
In terms of cytotoxicity, CPD3 is slightly superior to Dxd, and since Exatecan is not a substrate for MDR, it avoids drug resistance caused by ion channel efflux.
In in vivo gastric cancer PDX models, HDM2012 demonstrated a dose-dependent efficacy, achieving a tumor growth inhibition rate of 82-93%, even in cases previously resistant to Ironitecan and topoisomerase inhibitor toxin ADCs.
Additionally, in the MUC17 low-expressing pancreatic PDX model, HDM2012 also induced sustained tumor regression, with a tumor growth inhibition rate of 91.5%.
In terms of stability, CPD3 (DAR8) exhibits good plasma stability across different species. It shows extremely high stability in humans and monkeys, outperforming the control DS-8201’s linker-toxin Dxd.
In exploratory toxicology studies, the crab-eating macaque showed good tolerance to HDM2012 at 45 mpk, indicating that HDM2012 has excellent potential for treating gastrointestinal cancers.Overall, East China Pharmaceutical has fully transformed from external introduction to internal R&D, rapidly laying out several self-developed platform ADC drugs and efficiently initiating clinical trials, demonstrating its extraordinary determination. It is expected to become an important player in the domestic ADC drug field, and we look forward to hearing clinical success stories related to these drugs soon.For more information on the development landscape of antibody drugs, specific information, patents, and clinical progress, please visit the Umabs DB global database (www.umabs.com).Further Reading:The market demands high standardsAnother milestone: Sanofi’s OX40L antibody for atopic dermatitis achieves success in Phase III clinical trialsSecond-line gastric cancer: Bai Li Tian Heng’s HER2 ADC initiates the fourth Phase III clinical trialPeak performance: VEGF-related ADCsAccelerating progress: Pukang Pharmaceutical initiates clinical exploration of PD-L1/VEGF+ multiple ADC combinationsGynecological tumors: Bai Li Tian Heng’s EGFR/HER3 dual antibody ADC aims for the sixth breakthrough therapy designationTalent acquisitionThe complexities of internationalizationMoving forward amidst skepticism: PD-1/PD-L1 dual antibodiesSafety: A potential prerequisite for breakthroughs in ADC efficacyThe world’s first PD-L1 ADC enters Phase III; will it become the next hot topic?The king of conjugates: Hengrui Pharmaceutical has 13 ADCs and 5 RDC therapies in clinical trials, while LIV-1 ADC may be discontinuedWhy the calmness? AK112 becomes the world’s first therapy with significant OS in second-line lung cancer with EGFR mutationsSolid tumor TCE: Once again, the industry places its betsShijiazhuang Pharmaceutical Group: Balancing similar and innovative drugsQilu’s GPRC5D/CD3 dual antibody: Advancing to Phase III clinical trials in two yearsCan CanSino finally seize a hot topic?Diverse layouts: The pipeline matrix update of China BiologicsKelun Biotech: TROP2 ADC achieves sales of 302.36 million yuan in six monthsEGFR/c-Met dual antibody ADC: Chengfan Pharmaceutical submits its first INDShijiazhuang’s third HER2 ADC enters clinical trialsTurning waste into treasure? ALX may have found key biomarkers for CD47 therapyDark market surges over 200%: Yinuo Pharmaceutical to debut on the Hong Kong Stock Exchange tomorrowB7H3: Nocare Jianhua’s first ADC enters clinical trialsWCLC 2025: Progress on small cell lung cancer ADCsWCLC 2025: Detailed results of ivonescimab’s first global Phase III clinical trial to be announced soonDongyao Pharmaceutical: ADC cumulative service projects exceed 100Summit plans to submit the first marketing application for PD-1/VEGF in the US, with an additional issuance of up to $360 million in stockOnce again, moving forward: Nectin-4 ADC+PD-1 therapy for bladder cancer successfully completes Phase III clinical trialsMonoclonal antibodies: 50 years of ups and downsFour products aiming for breakthrough therapy: Rongchang’s PD-1/VEGF dual antibody, Lepu’s TF ADC, Decipher’s CLDN18.2 ADC, and Lixin’s CLDN18.2 ADCNovartis’s BAFF-R antibody for Sjögren’s syndrome achieves success in Phase III clinical trials, with domestic Shijian Biotech developing similar therapiesCollaboration only lasted a year: ROR1 ADC is returnedHLX43 shows significant efficacy in TSCC, Fuhong Hanlin begins international multi-center clinical layoutThe seventh CDH17 ADC enters clinical trials globallyAnother twist: Vinay Prasad will return to the FDAWorld’s first: Rongchang/Jiushi jointly submit HER ADC+PD-1 for first-line treatment of urothelial carcinomaBai Li Tian Heng submits its 11th ADC clinical trial applicationFirst-line gastric cancer head-to-head: Hengrui’s HER2 ADC initiates its 9th Phase III clinical trialBreaking conventional dosing: A new type of camptothecin ADCWeight loss star: Viking initiates two Phase III clinical trials for GLP-1/GIP agonistsMonth-on-month increase of 65%: Amgen’s DLL-3/CD3 dual antibody breaks $100 million in a single quarter for the first timeCombined with PD-L1: Hengrui initiates HER2 ADC breast cancer head-to-head Phase III clinical trialKangfang Yiwosi is about to initiate the first PD-1/VEGF+ADC combination therapyHan Sen iterates the application for subcutaneous EGFR/c-Met dual antibody?Roche develops targeted conjugates AOC, iterating the Brainshuttle platformOriginating from Han Sen: GSK initiates global Phase III clinical trials for B7H3 ADCWuXi Biologics publicly launches a three-antibody TCE platform, covering both hematological and solid tumors comprehensivelyOnly 8 months post-launch, Astellas’s CLDN18.2 antibody achieves quarterly sales of $22.82 million in ChinaPancreatic cancer: Lepu’s TF ADC initiates its first Phase III clinical trialAngling for a self-developed ADC platformFirst Takeda Q1: HER2 ADC underperforms expectations, TROP2 raises expectations, developing STING agonist ADCSanofi H1: Dupixent sells for €7.312 billionChinese and foreign pharmaceutical companies terminate the development of four antibodies$1.025 billion deal goes abroad: Hengrui’s long-acting TSLP antibody initiates its first Phase III clinical trialComparing K drug + chemotherapy: Innovent initiates clinical trials for PD-1/IL-2 lung cancer neoadjuvant combination therapyTurbulence continues: FDA CBER head to leave again, just three months into the roleMerck H1: K drug sells for $15.2 billionClosing in on AK112: Innovent is about to initiate PD-1/IL-2+VEGF combination therapyAZ’s half-year report: HER2 ADC sells for $2.289 billion, TROP2 ADC’s first sale reaches $14 millionAdaptimmune plummets 71%, first TCR-T cell therapy sold offESMO’s PD-1(L1)/VEGF appetizerBai Li Tian Heng submits its first radiolabeled conjugate drug applicationESMO’s ADC appetizerIs the end of BD the beginning of CDMO?Can we trust the words of the big shots?Kangfang’s PD-1/VEGF submits its third marketing application: possibly for the indication of combination chemotherapy in first-line lung cancerDark market surges 90%, Vili Zhibo to debut on the Hong Kong Stock Exchange tomorrowRoche’s TIGIT saga ends: all Phase III clinical trials terminated
About Umabs DB
Umabs DB is currently the most comprehensive global database for antibody drugs, recording nearly 10,000 antibody drugs from clinical trials to commercialization, covering over 1,600 targets and more than 2,400 disease types, with 2,900+ research institutions involved, encompassing various professional information such as drug protein sequences, patents, and clinical data. The Umabs DB drug database has officially launched and can be accessed at www.umabs.com for a 7-day free trial, for more information, please contact [email protected]
